Australia's healthcare firm Emyria jumps on new CBD capsule launch
17/03/2022 04:31
** Shares of healthcare co Emyria Ltd EMD.AX advance as
much as 10.7% to A$0.31, their best session since Jan. 12
** Says it has launched a new ultra-pure CBD formulation,
EMD-RX7, which has more than 4 times the bioavailability of an
equivalent dose of market-available CBD oil urn:newsml:reuters.com:*:nASX3Jk02S
** Higher bioavailability means a lower dose will be
required for the drug to have an active effect on the body
** Stock hits highest level since March 7
** As of last close, EMD has lost 27.3% this year
(Reporting by Harshita Swaminathan)
((Harshita.Swaminathan@thomsonreuters.com))